Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Updated Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
12-007

DRF is approved for relapsing forms of MS; it has the same pharmacologically active metabolite as dimethyl fumarate (DMF) and a similar efficacy and safety profile. Clinical studies of DRF demonstrated favorable gastrointestinal (GI) tolerability and a low rate of treatment discontinuation due to GI adverse events (AEs). Preliminary data suggest that MS patients treated with DRF have high rates of persistence and adherence in the real-world setting; however, those preliminary studies have included small patient numbers; evaluation of real-world DRF persistence in a larger patient population is needed.

To evaluate persistence and adherence in patients with multiple sclerosis (MS) treated with diroximel fumarate (DRF) in real-world clinical practice.

This retrospective analysis of the AcariaHealth Specialty Pharmacy Program included patients who initiated DRF from 01-Dec-2019 through 30-Jan-2021 with data extraction on 30-Jun-2021. Endpoints included persistence (proportion of patients remaining on therapy), discontinuation rate due to GI AEs, and adherence measured by proportion of days covered (PDC). GI AEs included: (a) GI-related AEs that occurred at any time or (b) any unknown AE that occurred ≤90 days after DRF initiation. 

Overall, 1,143 patients were included; 433 (38%) patients had been treated with prior DMF. Median (range) DRF treatment duration was 7.1 (0.1-20.0) months. The overall estimated proportion of patients remaining on DRF treatment at 16 months was 82.3% (95% CI 77.2-86.3). Fifty-two (4.5%) patients discontinued DRF due to GI AEs.  Mean PDC was 90.8% (95% CI, 89.2–92.5) and 85.4% (95% CI: 83.3-87.4) of patients achieved a PDC ≥80%.

In this analysis of >1,000 patients treated with DRF in real-world clinical practice, overall persistence at 16 months was high, treatment discontinuation due to GI AEs was low, and patients were highly adherent to therapy. 

Study Supported by: Biogen

Authors/Disclosures
Brittney Lager (AcariaHealth)
PRESENTER
Brittney Lager has received personal compensation for serving as an employee of AcariaHealth.
Jacob Liseno (AcariaHealth, Inc.) Jacob Liseno has nothing to disclose.
Catherine Miller Catherine Miller has received personal compensation for serving as an employee of Biogen. Catherine Miller has received stock or an ownership interest from Biogen.
Sai *use 234396 Shankar (Biogen) No disclosure on file
Jason P. Mendoza (Biogen) No disclosure on file
James B. Lewin, PharmD Dr. Lewin has received personal compensation for serving as an employee of Biogen. Dr. Lewin has stock in Biogen.